A few weeks after announcing a number of new export- and investment promotion initiatives in the wake of the covid-19 crisis, Denmark is now attracting one of the largest foreign investments into Denmark ever recorded.

With its new capital investment FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO) for biologics and advanced therapies, will double the current drug substance manufacturing capacity in their facilities in Hillerød in Denmark, and will expand its capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services.

The investment also means that the site will become one of the few major largescale manufacturing facilities in the global bio-CDMO industry and become a flagship facility for FUJIFILM Diosynth Biotechnologies.

“Since the acquisition of the site last year, the facility's strong manufacturing track-record, coupled with FUJIFILM Diosynth Biotechnologies' technologies enabling a stable supply of high-quality biopharmaceuticals, has led to new orders not only from existing clients, but also new clients, contributing to our rapid business expansion.”

Mr. Ishikawa, Director

Executive Vice President from FUJIFILM Corporation

FUJIFILM Diosynth Biotechnologies acquired the site in Denmark from the American company Biogen in August last year. In April 2020, FUJIFILM Diosynth Biotechnologies announced that it will reserve manufacturing capacity for a future COVID-19 therapy for the COVID-19 Therapeutics Accelerator - an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed-up the response to the global pandemic.

“Foreign companies investing in Denmark are an important part of Denmark’s business community. Recently, the Danish government launched a new strategy for attracting sustainable foreign investments contributing to the government’s ambition of pursuing an active business policy. The life science sector is a key focus area in the strategy as Denmark besides a stable business environment offers international life science companies an innovative environment, high productivity, sustainable production and a green profile. This milestone investment by FUJIFILM Diosynth Biotechnologies is a testament to that fact.”

Jeppe Kofod

Minister for Foreign Affairs